Oncogene-addicted non-small cell lung cancer and immunotherapy

Area of Science:

• Oncology
• Cancer Research
• Precision Medicine

Background:

• Non-small cell lung cancer (NSCLC) frequently harbors oncogenic driver mutations, making them susceptible to targeted therapies like tyrosine kinase inhibitors (TKIs).
• Immunotherapy (IO), specifically immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) or PD-L1, has significantly improved survival in NSCLC compared to chemotherapy.
• The efficacy and optimal sequencing of IO in oncogene-addicted NSCLC, especially following TKI treatment, remain areas of active research.

Purpose of the Study:

• To review current evidence on the use of immunotherapy in oncogene-addicted non-small cell lung cancer.
• To identify key questions and future research directions for defining the role of IO in this patient population.

Main Methods:

• Literature review of clinical data and subgroup analyses.
• Synthesis of existing evidence regarding immunotherapy use in NSCLC with specific driver mutations.

Main Results:

• While TKIs have revolutionized NSCLC treatment, the benefit of IO after TKI therapy in oncogene-addicted NSCLC is not well-established.
• Current data, often from small subgroup analyses, do not strongly support the use of IO after TKI in this specific NSCLC subgroup.

Conclusions:

• The role of immunotherapy in oncogene-addicted NSCLC requires further clarification.
• Future research should focus on addressing specific clinical questions to determine the optimal use of IO in these patients.